Evidence map›Paper›PMID 25351806›Full record

ArticleOncology reports2015

A retrospective examination of mean relative telomere length in the Tasmanian Familial Hematological Malignancies Study.

Nicholas B Blackburn, Jac C Charlesworth, James R Marthick, Elizabeth M Tegg, Katherine A Marsden, Velandai Srikanth, John Blangero, Ray M Lowenthal, Simon J Foote, Joanne L Dickinson

Open access · hybridAbstract read
In one paragraph

Article in Oncology reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Heritability of telomere variation: it is all about the environment!Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2018
    Review
  4. Article
  5. Relative Telomere Length before Hematopoietic Cell Transplantation and Outcome after Unrelated Donor Hematopoietic Cell Transplantation for Acute Leukemia.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Nicholas B BlackburnMenzies Research Institute Tasmania, University of Tasmania, Hobart, TAS 7000, Australia.
Jac C CharlesworthMenzies Research Institute Tasmania, University of Tasmania, Hobart, TAS 7000, Australia.
James R MarthickMenzies Research Institute Tasmania, University of Tasmania, Hobart, TAS 7000, Australia.
Elizabeth M TeggRoyal Hobart Hospital, Hobart, TAS 7001, Australia.
Katherine A MarsdenMenzies Research Institute Tasmania, University of Tasmania, Hobart, TAS 7000, Australia.
Velandai SrikanthDepartment of Medicine, Monash Medical Centre, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, VIC 3168, Australia.
John BlangeroDepartment of Genetics, Texas Biomedical Research Institute, San Antonio, TX 78245-0549, USA.
Ray M LowenthalMenzies Research Institute Tasmania, University of Tasmania, Hobart, TAS 7000, Australia.
Simon J FooteJohn Curtain School of Medical Research, Australian National University, ACT 2601, Australia.
Joanne L DickinsonMenzies Research Institute Tasmania, University of Tasmania, Hobart, TAS 7000, Australia.
University of Tasmania · AUAustralian National University · AUAustralian Regenerative Medicine Institute · AURoyal Hobart Hospital · AUTexas Biomedical Research Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Telomere length has a biological link to cancer, with excessive telomere shortening leading to genetic instability and resultant malignant transformation. Telomere length is heritable and genetic variants determining telomere length have been identified. Telomere biology has been implicated in the development of hematological malignancies (HMs), therefore, closer examination of telomere length in HMs may provide further insight into genetic etiology of disease development and support for telomere length as a prognostic factor in HMs. We retrospectively examined mean relative telomere length in the Tasmanian Familial Hematological Malignancies Study using a quantitative PCR method on genomic DNA from peripheral blood samples. Fifty-five familial HM cases, 191 unaffected relatives of familial HM cases and 75 non-familial HM cases were compared with 758 population controls. Variance components modeling was employed to identify factors influencing variation in telomere length. Overall, HM cases had shorter mean relative telomere length (p=2.9×10-6) and this was observed across both familial and non-familial HM cases (p=2.2x10-4 and 2.2x10-5, respectively) as well as additional subgroupings of HM cases according to broad subtypes. Mean relative telomere length was also significantly heritable (62.6%; p=4.7x10-5) in the HM families in the present study. We present new evidence of significantly shorter mean relative telomere length in both familial and non-familial HM cases from the same population adding further support to the potential use of telomere length as a prognostic factor in HMs. Whether telomere shortening is the cause of or the result of HMs is yet to be determined, but as telomere length was found to be highly heritable in our HM families this suggests that genetics driving the variation in telomere length is related to HM disease risk.

Indexed as

Telomere ShorteningAdolescentAdultAgedAged, 80 and overFemaleHematologic NeoplasmsHumansMaleMiddle AgedRetrospective StudiesRisk FactorsTasmaniaYoung Adult

Identifiers

PMID25351806
PMCPMC4254675
OpenAlexW2020556873

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.